Outcomes Following Bronchial Artery Embolisation for Haemoptysis in Cystic Fibrosis

Abstract

Bronchial artery embolisation (BAE) is recommended for the treatment of massive haemoptysis in cystic fibrosis (CF), but there are no randomised controlled trials of this therapy and its role in sub-massive haemoptysis is unclear. This study aimed to determine the outcomes and safety of BAE in adults with CF. All patients with CF undergoing BAE at our centre between March 2011 and January 2015 were identified at the time of the procedure. Patient records were reviewed at hospital discharge, death or one month post-procedure (whichever was soonest). Follow-up continued to January 2016. Severity of haemoptysis was classified as: massive (>240 ml/24 h or >100 ml/day for ≥2 days), moderate–severe (>20 ml/24 h) or mild (<20 ml/24 h). Twenty-seven patients underwent 51 BAE procedures over a median follow-up period of 26 months (range 1–54). Ten patients (37%) required more than one BAE during the study. BAE was performed for massive haemoptysis in 18 cases (35%). Haemoptysis recurred after 31 (61%) of BAE procedures with no difference in recurrence rates between massive and sub-massive haemoptysis. Side effects were reported after 61% of procedures with chest pain the most common adverse event . Mortality after first BAE in the study was 3.9% at 30 days and 14.8% at 12 months. No significant predictors of mortality were identified. BAE is often effective in controlling haemoptysis but is associated with considerable morbidity and high recurrence rates.

DOI: 10.1007/s00270-017-1626-0

4 Figures and Tables

Cite this paper

@article{Flight2017OutcomesFB, title={Outcomes Following Bronchial Artery Embolisation for Haemoptysis in Cystic Fibrosis}, author={William George Flight and Pat J Barry and Rowland J Bright-Thomas and Stephen A. Butterfield and Ray Ashleigh and Andrew M. Jones}, journal={CardioVascular and Interventional Radiology}, year={2017}, volume={40}, pages={1164-1168} }